EUnetHTA project plan for Stereotactic Body Radiation Therapy (SBRT) for lung, prostate and liver cancer

28

Aug 2020

In July 2020, the network of European HTA agencies, EUnetHTA, announced a final project plan of the project OTCA25 “Stereotactic Body Radiation Therapy (SBRT) for lung, prostate, and liver cancer.”

This project is being executed by the Agency for Health Quality Assessment of Catalonia (AQuAS) in Spain and the Agency for Health Technology Assessment and Tariff System (AOTMIT) in Poland. The dedicated reviewers are Swiss Network for Health Technology Assessment (SNHTA), Italian Azienda Zero from Veneto Region, and Spanish Health Institute Carlos III (ISCIII).

The rationale of this assessment is to collaboratively produce structured (rapid) core HTA information on other technologies. The purpose is to apply those collaboratively produced assessments in the national or regional context.

This rapid assessment addresses the research question: to compare the effectiveness, safety of SBRT, and standard of care therapies in lung, prostate, and liver cancer.

This topic was chosen based on a request from the Spanish Commission on Benefits, Entitlement, and Financing (CPAF) who commissioned AQuAS to do an HTA on SBRT in lung, prostate, and liver cancer.

The relevance of the topic lies in the fact that there are uncertainties, controversies, and lack of consensus on the additional value of SBRT, as it can be considered to be expensive technology. Moreover, the number of linear accelerators available in Spain with SBRT has tripled in the last three years, making the technology more available.

The HTA Core Mode Applications for Rapid Relative Effectiveness Assessment Version 4.2. will be the primary source for selecting assessment elements.

For Effectiveness (EFF) and Safety (SAF) domains, a systematic literature search will be performed using the bibliographic databases: Cochrane Library (Wiley), Medline (PubMed), Embase (Ovid). A specific search for ongoing clinical trials will be conducted at Clinicaltrials.gov, Cochrane Central EU clinical trials, and International ClinicalTrials Registry Platform (ICTRP). In addition to the electronic search, a manual revision of the bibliographic references cited in the selected papers, as well as a general internet search for scientific journal articles and a revision of sources and guidelines recommended by the external experts, will be performed. The following publication types will be excluded: case reports, letters, congress abstracts, or editorials.

The final version of this rapid assessment is expected to be published in November 2020.

The full details in English can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

14

May 2021

In late April 2021, the European Network for Health Technology Assessment, EUnetHTA, in partnership with the Austrian Institute for HTA (AIHTA), released a final report on the comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia. Twenty-one minimally invasive surgical treatments for benign prostatic hyperplasia were compared. Newer technologies may offer some advantage over transurethral resection of the prostate by reducing the transfusion requirement.

Read more

12

May 2021

The Agency for Health Technology Assessment of Andalusia Autonomous Community in Spain (AETSA) systematically evaluates healthcare technologies and provides decision-makers with critically review information about their efficacy, safety, and effectiveness. Currently, the AETSA is working on assessments of laser-induced heat therapy in epilepsy surgery, stereotactic radiation therapy for the treatment of refractory ventricular tachycardia, implantable Holter monitor with ILink Online technology for prolonged cardiac monitoring, and other topics.

Read more

11

May 2021

In late April and early May 2021, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, fifteen health apps are now available at the DiGA Directory.

Read more

10

May 2021

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 6462 of April 21, 2021, Tuscany Regional Healthcare has published assessments of six medical devices of various therapeutic areas, including devices for the treatment of vaginal prolapse, cardiovascular conditions, an implant for vocal cord rehabilitation, and a cerebral embolic protective device.

Read more

06

May 2021

The Treatment Council (Behandlingsråd) is a new model for assessing treatment methods and health technologies, expected to become fully operational during 2021. The first meeting of the Treatment Council is planned to be conducted in May 2021. On April 15, 2021, the method and process frameworks of the Treatment Council (Behandlingsråd) were sent for consultation to the parties who have previously submitted consultation responses regarding these documents.

Read more